CD274 and non-small cell lung carcinoma: In recent years, immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway have made breakthroughs in the treatment of NSCLC, which are more effective and safer compared with conventional treatments (8–10).